Select Page

Cosmeceuticals

Details

Cosmeceuticals

The main physiological function of the cutaneous ECS is to constitutively control the proper and well-balanced proliferation, differentiation and survival, as well as immune competence and tolerance, of skin cells. The use of CBD internally or as a skin lotion, patch, or oil maintains this delicate balance and may prevent from pathological conditions and diseases of the skin (e.g. acne, seborrhea, allergic dermatitis, itch and pain, psoriasis, hair growth disorders, and systemic sclerosis).

Chief Science Officer

Vanesa Fernandez, PhD

Vanesa Fernandez’s journey in the cannabinoid space began in 2006 with Amsterdam’s Echo Pharmaceuticals. She took the helm as CEO in 2010, and grew the company from a start-up to a mature pharmaceutical company. Its extensive clinical program included 9+ trials in the CNS and pain space. Vanesa developed an IP strategy to protect the company’s formulation technology, leading to two distinctive market-ready pharmaceutical products.

In 2018, Vanesa founded OCHO Amsterdam BV, a company developing and producing high quality cannabinoid products for the European market. She also consulted in the cannabis field, providing scientific advice to both European and American companies on pharmaceutical developments.

Previously, Vanesa worked as Project leader for Amsterdam’s FeyeCon D&I, the company Folium Biosciences recently acquired. She led the company in carbon dioxide technology by creating sustainable products and processes in various verticals such as pharmaceutical, pharma textile, food and cosmetics. As project Leader, she managed different commercial development projects for international clients and set up GMP quality systems.

Vanesa earned her PhD in Chemistry at the Netherland’s Delft University of Technology on textile dyeing with carbon dioxide. She holds a MSc. degree in Chemistry from Spain’s University of Santiago de Compostela.

Call Now Button